Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

Abstract

Background:

Dimethyl fumarate (DMF) is a disease-modifying therapy used for patients with relapsing-remitting multiple sclerosis (RRMS). B cells are important contributors to the pathogenesis of RRMS, where they regulate the inflammatory immune responses and participate in development of lesions in the central nervous system (CNS). The impact of DMF on B cell subpopulations remains incompletely understood.

Objectives:

In this study, we evaluated the effects of DMF on B cell subpopulations and their effector functions.

Methods:

Blood from 21 DMF-treated and 18 untreated patients with RRMS was analyzed by flow cytometry.

Results:

We found that DMF reduces the frequency of circulating antigen–experienced B cells, a reduction likely related to a reduced frequency of follicular helper T (T_FH) cells and an increased frequency of follicular regulatory T (T_FR) cells. Studying the impact of monomethyl fumarate (MMF), the primary metabolite of DMF, on B cell effector function in vitro showed that MMF increased the frequency of transforming growth factor (TGF)-β-producing B cells and decreased the frequency of B cells secreting lymphotoxin (LT)-α, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and to a lesser extent IL-10.

Conclusion:

In summary, these data suggest an anti-inflammatory role of DMF and its metabolite MMF on the B cell compartment.

Keywords

Multiple sclerosis dimethyl fumarate B cells cytokines follicular helper T cells

Get full access to this article

View all access options for this article.

References

Lemus

Warrington

Rodriguez

. Multiple sclerosis: Mechanisms of disease and strategies for myelin and axonal repair. Neurol Clin 2018; 36(1): 1–11.

Dendrou

Fugger

Friese

. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015; 15(9): 545–558.

Bar-Or

Gold

Kappos

, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of the DEFINE study. J Neurol 2013; 260(9): 2297–2305.

Fox

Miller

Phillips

, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367(12): 1087–1097.

Gold

Kappos

Arnold

, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098–1107.

Van Horssen

De Vries

. Dimethyl fumarate: A novel oral front-line therapy for multiple sclerosis treatment. Future Neurol 2013; 8(3): 247–254.

Berkovich

Weiner

. Effects of dimethyl fumarate on lymphocyte subsets. Mult Scler Relat Disord 2015; 4(4): 339–341.

Linker

Lee

Ryan

, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134(Pt 3): 678–692.

Tahvili

Zandieh

Amirghofran

. The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis. Int J Dermatol 2015; 54(7): e254–e260.

10.

Lundy

Wang

, et al. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm 2016; 3(2): e211.

11.

Rezk

Ghadiri

, et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J Immunol 2017; 198(2): 691–698.

12.

Smith

Martin

Calabresi

, et al. Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. Ann Clin Transl Neurol 2017; 4(5): 351–355.

13.

Longbrake

Cantoni

Chahin

, et al. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. Mult Scler 2015; 24: 728–738.

14.

Morita

Schmitt

Bentebibel

, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011; 34(1): 108–121.

15.

Dhaeze

Stinissen

Liston

, et al. Humoral autoimmunity: A failure of regulatory T cells? Autoimmun Rev 2015; 14(8): 735–741.

16.

Mesquita

Cruvinel

Resende

, et al. Follicular helper T cell in immunity and autoimmunity. Braz J Med Biol Res 2016; 49(5): e5209.

17.

Wang

Zhou

, et al. The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin Immunol 2017; 183: 46–53.

18.

Dhaeze

Peelen

Hombrouck

, et al. Circulating follicular regulatory T cells are defective in multiple sclerosis. J Immunol 2015; 195(3): 832–840.

19.

Benjamin

Berger

Johannesson

, et al. Redefine statistical significance. Nature Human Behav 2018; 2(1): 6–10.

20.

Bao

Cao

. The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review. J Autoimmun 2014; 55: 10–23.

21.

Ghadiri

Rezk

, et al. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm 2017; 4(3): e340.

22.

Fleischer

Friedrich

Rezk

, et al. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. Mult Scler 2018; 24(5): 632–641.

23.

Barr

Shen

Brown

, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209(5): 1001–1010.

24.

Rezk

Miyazaki

, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015; 7(310): 310ra166.

25.

Miyazaki

Rezk

, et al. A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected]. PLoS ONE 2014; 9(8): e105421.

26.

Bar-Or

Fawaz

Fan

, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67(4): 452–461.

27.

Duddy

Niino

Adatia

, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178(10): 6092–6099.

28.

Kornberg

Bhargava

Kim

, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 2018; 360(6387): 449–453.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.34 MB